Integral Molecular initiates therapeutic target discovery program

Medigene expands Bluebird bio alliance in cancer immunotherapy
Credit: fusebulb

Integral Molecular has initiated a therapeutic target discovery program in immuno-oncology by exploiting its Membrane Proteome Array technology to identify cell-surface proteins involved in regulating the ability of the human immune system to recognise and destroy cancer.

The Membrane Proteome Array is a cell-based screening platform composed of 5,300 unique membrane proteins expressed in live human cells.

Using this technology, the company has identified entirely novel immuno-oncology protein interactions, as well as validated therapeutic axes such as PD1/PD-L1.

The Membrane Proteome Array is ideally suited to the discovery of new therapeutic targets because each membrane protein is expressed in its functional form on the surface of live human cells, enabling signaling and binding assays to detect functional interactions.

In addition, the 5,300 membrane proteins that form the platform represent the largest library of its kind, including over 95% of all known IgV-set proteins and GPCRs.

“No other platform has systematically explored the role of GPCRs, ion channels, and transporters in the immuno-oncology space,” says Benjamin Doranz, CEO of Integral Molecular, adding that “our capabilities in this area have already resulted in the discovery of new immune protein interactions, and we expect to identify more with our novel approach”.